Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Understanding the glioblastoma immune microenvironment as basis for the development of new immunotherapeutic strategies
Ana Rita Pombo Antunes, Isabelle Scheyltjens, Johnny Duerinck, et al.
eLife (2020) Vol. 9
Open Access | Times Cited: 228

Showing 1-25 of 228 citing articles:

Single-cell profiling of myeloid cells in glioblastoma across species and disease stage reveals macrophage competition and specialization
Ana Rita Pombo Antunes, Isabelle Scheyltjens, Francesca Lodi, et al.
Nature Neuroscience (2021) Vol. 24, Iss. 4, pp. 595-610
Open Access | Times Cited: 470
Advances in local therapy for glioblastoma — taking the fight to the tumour
Thomas S. van Solinge, Lisa Nieland, E. Antonio Chiocca, et al.
Nature Reviews Neurology (2022) Vol. 18, Iss. 4, pp. 221-236
Open Access | Times Cited: 215
Tumor Cell Invasion in Glioblastoma
Arabel Vollmann‐Zwerenz, Verena Leidgens, Giancarlo Feliciello, et al.
International Journal of Molecular Sciences (2020) Vol. 21, Iss. 6, pp. 1932-1932
Open Access | Times Cited: 214
Conventional DCs sample and present myelin antigens in the healthy CNS and allow parenchymal T cell entry to initiate neuroinflammation
Sarah Mundt, Dunja Mrdjen, Sebastian G. Utz, et al.
Science Immunology (2019) Vol. 4, Iss. 31
Open Access | Times Cited: 210
T-cell dysfunction in the glioblastoma microenvironment is mediated by myeloid cells releasing interleukin-10
Vidhya M. Ravi, Nicolas Neidert, Paulina Will, et al.
Nature Communications (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 202
A Review of Newly Diagnosed Glioblastoma
Bryan Oronsky, Tony R. Reid, Arnold L. Oronsky, et al.
Frontiers in Oncology (2021) Vol. 10
Open Access | Times Cited: 130
Hypoxic niches attract and sequester tumor-associated macrophages and cytotoxic T cells and reprogram them for immunosuppression
Anirudh Sattiraju, Sang Jo Kang, Bruno Giotti, et al.
Immunity (2023) Vol. 56, Iss. 8, pp. 1825-1843.e6
Open Access | Times Cited: 110
Sex-Specific Differences in Glioblastoma
Anna Carrano, Juan José Juárez‐Vignon Whaley, Diego Incontri‐Abraham, et al.
Cells (2021) Vol. 10, Iss. 7, pp. 1783-1783
Open Access | Times Cited: 106
Signaling pathways and therapeutic approaches in glioblastoma multiforme (Review)
Marsel Khabibov, Айрат Гарифуллин, Yanis Boumber, et al.
International Journal of Oncology (2022) Vol. 60, Iss. 6
Open Access | Times Cited: 76
Neutralizing IL-8 potentiates immune checkpoint blockade efficacy for glioma
Haofei Liu, Qiwen Zhao, Leyong Tan, et al.
Cancer Cell (2023) Vol. 41, Iss. 4, pp. 693-710.e8
Open Access | Times Cited: 63
Understanding the immunosuppressive microenvironment of glioma: mechanistic insights and clinical perspectives
Hao Lin, Chaxian Liu, An-Kang Hu, et al.
Journal of Hematology & Oncology (2024) Vol. 17, Iss. 1
Open Access | Times Cited: 62
Immunotherapy in glioblastoma treatment: Current state and future prospects
Samuel Luca Rocha Pinheiro, Fabian Fellipe Bueno Lemos, Hanna Santos Marques, et al.
World Journal of Clinical Oncology (2023) Vol. 14, Iss. 4, pp. 138-159
Open Access | Times Cited: 51
Glioblastoma: An Update in Pathology, Molecular Mechanisms and Biomarkers
Zhong Lan, Xin Li, Xiao-Qin Zhang
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 5, pp. 3040-3040
Open Access | Times Cited: 33
Temozolomide (TMZ) in the Treatment of Glioblastoma Multiforme—A Literature Review and Clinical Outcomes
Marcin Jezierzański, Natalia Nafalska, Małgorzata Stopyra, et al.
Current Oncology (2024) Vol. 31, Iss. 7, pp. 3994-4002
Open Access | Times Cited: 30
Glioblastoma vaccines: past, present, and opportunities
Zujian Xiong, Itay Raphael, Michael R. Olin, et al.
EBioMedicine (2024) Vol. 100, pp. 104963-104963
Open Access | Times Cited: 29
Decoding the spatiotemporal heterogeneity of tumor-associated macrophages
Xiangyuan Chu, Yu Tian, Chao Lv
Molecular Cancer (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 19
Glioblastoma multiforme: insights into pathogenesis, key signaling pathways, and therapeutic strategies
Ashkan Pouyan, Masoud Ghorbanlo, Masoud Eslami, et al.
Molecular Cancer (2025) Vol. 24, Iss. 1
Open Access | Times Cited: 2
Myeloid Cells in Glioblastoma Microenvironment
Alessandra De Leo, Alessio Ugolini, Filippo Veglia
Cells (2020) Vol. 10, Iss. 1, pp. 18-18
Open Access | Times Cited: 115
G-CSF secreted by mutant IDH1 glioma stem cells abolishes myeloid cell immunosuppression and enhances the efficacy of immunotherapy
Mahmoud S. Alghamri, Brandon L. McClellan, Ruthvik Avvari, et al.
Science Advances (2021) Vol. 7, Iss. 40
Open Access | Times Cited: 75
Immunotherapy of Glioblastoma: Current Strategies and Challenges in Tumor Model Development
Bernarda Majc, Metka Novak, Nataša Kopitar‐Jerala, et al.
Cells (2021) Vol. 10, Iss. 2, pp. 265-265
Open Access | Times Cited: 71
Rationally designed drug delivery systems for the local treatment of resected glioblastoma
Chiara Bastiancich, Alessio Malfanti, Véronique Préat, et al.
Advanced Drug Delivery Reviews (2021) Vol. 177, pp. 113951-113951
Open Access | Times Cited: 70
Microglia and astrocyte involvement in neurodegeneration and brain cancer
Arthur A. Vandenbark, Halina Offner, Szymon Matejuk, et al.
Journal of Neuroinflammation (2021) Vol. 18, Iss. 1
Open Access | Times Cited: 63
Multispecific targeting of glioblastoma with tumor microenvironment-responsive multifunctional engineered NK cells
Jiao Wang, Sandra Toregrosa-Allen, Bennett D. Elzey, et al.
Proceedings of the National Academy of Sciences (2021) Vol. 118, Iss. 45
Open Access | Times Cited: 61
Current knowledge on the immune microenvironment and emerging immunotherapies in diffuse midline glioma
Gabrielle Price, Alexandros Bouras, Dolores Hambardzumyan, et al.
EBioMedicine (2021) Vol. 69, pp. 103453-103453
Open Access | Times Cited: 57
Reprogramming systemic and local immune function to empower immunotherapy against glioblastoma
Songlei Zhou, Yukun Huang, Yu Chen, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 41
Page 1 - Next Page

Scroll to top